Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585000 · ClinicalTrials.gov registry record · Phase 1
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00585000 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 49 participants.
The verdict
NCT00585000, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.
Interventions
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585000
The ClinicalTrials.gov registry entry for NCT00585000 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-675,206 is the first listed.
NCT00585000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585000 about?
NCT00585000 is a clinical study titled "A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma". This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.
What is the current status of trial NCT00585000?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2007-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00585000?
The interventions under investigation include: CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00585000?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.